Xenon Pharmaceuticals Inc.

Thank you for standing by. My name is Carly and I will be your conference operator today. At this time, I would like to welcome everyone to the Q1 2025 Xenon Pharmaceuticals Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Chad Fougere, Xenon's Vice President of Investor Relations. Please go ahead.

Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's first quarter 2025 financial and operating results. Joining me are Ian Mortimer, Xenon's President and Chief Executive Officer, Dr. Chris Kenney, Xenon's Chief Medical Officer, and Sherry Allen, Xenon's Chief Financial Officer. After completing their prepared remarks today, we will open the call out for your questions. Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from clinical trials, the potential efficacy, safety profile, future development plans, and current and anticipated indications, addressable markets, regulatory success and commercial potential of our and our partners' product candidates, the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in our clinical development program, including the anticipated filing of INDs and NDAs, the timing and results of those filings, and our interactions with regulators, our ability to successfully obtain regulatory approvals, anticipated timing of the top-line data readout for our clinical trials at the Zetsu calendar, and our expectation that we will have sufficient cash to fund operations into 2027. Today's press release summarizing Xenon's first quarter financial results and the accompanying quarterly report on Form 10Q will be made available under the investor section of our website at xenon-pharma.com and filed with the SEC and on CEDAR+. Now, I would like to turn the call over to Ian.

Thanks, Chad, and good afternoon, everyone, and thanks for joining our call today.